69 related articles for article (PubMed ID: 29797219)
1. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells.
Twum Y; Marshall K; Gao W
Biofactors; 2023; 49(6):1143-1157. PubMed ID: 37555475
[TBL] [Abstract][Full Text] [Related]
5. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
[TBL] [Abstract][Full Text] [Related]
6. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
[TBL] [Abstract][Full Text] [Related]
7. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Thress KS; Paweletz CP; Felip E; Cho BC; Stetson D; Dougherty B; Lai Z; Markovets A; Vivancos A; Kuang Y; Ercan D; Matthews SE; Cantarini M; Barrett JC; Jänne PA; Oxnard GR
Nat Med; 2015 Jun; 21(6):560-2. PubMed ID: 25939061
[TBL] [Abstract][Full Text] [Related]
8. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
[TBL] [Abstract][Full Text] [Related]
9. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.
Shang JL; Ning SB; Chen YY; Chen TX; Zhang J
Acta Pharmacol Sin; 2021 Jan; 42(1):120-131. PubMed ID: 32541922
[TBL] [Abstract][Full Text] [Related]
10. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
[TBL] [Abstract][Full Text] [Related]
11. Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling.
Lai L; Shen Q; Wang Y; Chen L; Lai J; Wu Z; Jiang H
Toxicol Appl Pharmacol; 2021 May; 419():115518. PubMed ID: 33812963
[TBL] [Abstract][Full Text] [Related]
12. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Galvani E; Sun J; Leon LG; Sciarrillo R; Narayan RS; Sjin RT; Lee K; Ohashi K; Heideman DA; Alfieri RR; Heynen GJ; Bernards R; Smit EF; Pao W; Peters GJ; Giovannetti E
Oncotarget; 2015 Dec; 6(40):42717-32. PubMed ID: 26015408
[TBL] [Abstract][Full Text] [Related]
13. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis.
Zhou Y; Huang S; Guo Y; Ran M; Shan W; Chen WH; Tam KY
Phytother Res; 2023 Dec; 37(12):5837-5853. PubMed ID: 37621136
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibitors against MET-amplified non-small cell lung cancer.
Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.
Liu X; Mei W; Zhang P; Zeng C
Pharmacol Res; 2024 Apr; 202():107123. PubMed ID: 38432445
[TBL] [Abstract][Full Text] [Related]
17. ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.
De Rosa C; De Rosa V; Tuccillo C; Tirino V; Amato L; Papaccio F; Ciardiello D; Napolitano S; Martini G; Ciardiello F; Morgillo F; Iommelli F; Della Corte CM
Sci Rep; 2024 Jan; 14(1):500. PubMed ID: 38177190
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Song KA; Niederst MJ; Lochmann TL; Hata AN; Kitai H; Ham J; Floros KV; Hicks MA; Hu H; Mulvey HE; Drier Y; Heisey DAR; Hughes MT; Patel NU; Lockerman EL; Garcia A; Gillepsie S; Archibald HL; Gomez-Caraballo M; Nulton TJ; Windle BE; Piotrowska Z; Sahingur SE; Taylor SM; Dozmorov M; Sequist LV; Bernstein B; Ebi H; Engelman JA; Faber AC
Clin Cancer Res; 2018 Jan; 24(1):197-208. PubMed ID: 29051323
[No Abstract] [Full Text] [Related]
19. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
Ortiz-Cuaran S; Scheffler M; Plenker D; Dahmen L; Scheel AH; Fernandez-Cuesta L; Meder L; Lovly CM; Persigehl T; Merkelbach-Bruse S; Bos M; Michels S; Fischer R; Albus K; König K; Schildhaus HU; Fassunke J; Ihle MA; Pasternack H; Heydt C; Becker C; Altmüller J; Ji H; Müller C; Florin A; Heuckmann JM; Nuernberg P; Ansén S; Heukamp LC; Berg J; Pao W; Peifer M; Buettner R; Wolf J; Thomas RK; Sos ML
Clin Cancer Res; 2016 Oct; 22(19):4837-4847. PubMed ID: 27252416
[TBL] [Abstract][Full Text] [Related]
20. [Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of
Non-small Cell Lung Cancer with MET Alterations].
Li S; Zhang X
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):684-691. PubMed ID: 37985154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
